# Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia

> **NCT01659021** · PHASE3 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 261 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Idelalisib
- **DRUG:** Ofatumumab

## Key facts

- **NCT ID:** NCT01659021
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-12-04
- **Primary completion:** 2018-08-15
- **Final completion:** 2018-08-15
- **Target enrollment:** 261 (ACTUAL)
- **Last updated:** 2019-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01659021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01659021, "Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01659021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*